After systematically identifying hypertension trials of drugs acting on the renin-angiotensin-aldosterone system, we showed that trials focusing on older people had a significantly higher rate of serious adverse events than comparator trials that did not focus specifically on older people (ie, standard trials). Here, REN is linked to hypertensive disorder.